SCHEMBL929208

SCHEMBL929208

CN1NCCc2c(-c3ccnc(F)c3)cccc21

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 3/20 0.47
PARP11 Q9NR21 3/20 0.47
PARP15 Q460N3 1/20 0.37
PARP14 Q460N5 1/20 0.37
TIPARP Q7Z3E1 1/20 0.37
PARP16 Q8N5Y8 1/20 0.37
AKT1 P31749 1/20 0.36
MAPK14 Q16539 2/20 0.35
GRM5 P41594 1/20 0.35
GRM1 Q13255 1/20 0.35
DYRK1A Q13627 2/20 0.34
NFATC1 O95644 1/20 0.34
RPS6KA3 P51812 1/20 0.34
UCHL1 P09936 2/20 0.33
DHFR P00374 1/20 0.33
IDO1 P14902 1/20 0.33
ADORA2B P29275 1/20 0.33
SYK P43405 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL929250 0.81 PARP10 (0.40) PARP10PARP11AKT1GRM5DYRK1A
SCHEMBL930330 0.80 PARP10 (0.42) PARP10PARP11MAPK14GRM5GRM1
SCHEMBL12905379 0.79 PARP10 (0.40) PARP10PARP11AKT1GRM5GRM1
SCHEMBL929498 0.75 PARP10 (0.39) PARP10PARP11MAPK14RPS6KA3DHFR
SCHEMBL929103 0.75 PARP10 (0.39) PARP10PARP11MAPK14RPS6KA3DHFR
SCHEMBL930304 0.72 NOTUM (0.45) AKT1
SCHEMBL931093 0.69 NOTUM (0.50) AKT1
SCHEMBL30775304 0.68 PIK3CD (0.57) PARP10PARP11DYRK1A
SCHEMBL929251 0.67 PARP10 (0.42) PARP10PARP11AKT1DYRK1AUCHL1
SCHEMBL929627 0.67 HTR2C (0.44) PARP10PARP11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003820-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE MERZ PHARMA GMBH & CO. KGAA (DE) 2011-01-06 US disclosed
EP-2090576-A1 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators Merz Pharma GmbH & Co.KGaA (DE) 2009-08-19 EP disclosed
WO-2009095253-A1 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2009-08-06 WO disclosed
WO-2009095253-A1 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2009-08-06 WO disclosed
EP-2085398-A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine Merz Pharma GmbH & Co. KGaA (DE) 2009-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003820-A1 PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE GRM5, GRIK5, GRK5 PARP10 2343/4885PARP11 2659/4885PARP15 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.